Sensyne Health plc, the British clinical AI technology company, today announces that it has signed an initial two-year collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using Sensyne Health’s proprietary clinical AI technology platform.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
